UnknownNCT05986734

Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies

Studying Primary immunodeficiency

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Principal Investigator
Anna Shcherbina, MD,Phd
Chief HSCT department at Federal Research Center for pediatric hematology, oncology and immunology
Intervention
Cutaquig(drug)
Enrollment
100 enrolled
Eligibility
18 years · All sexes
Timeline
20222023

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05986734 on ClinicalTrials.gov

Other trials for Primary immunodeficiency

Additional recruiting or active studies for the same condition.

See all trials for Primary immunodeficiency

← Back to all trials